Home
About
Products
Research
Markets
Contact
News
Publications


The market potential for the Company's lead products is significant. ProCertus estimates the U.S. commercial markets for ProDermaCel™, DermX and OralX as $400 MM, $350 MM and $500 MM, respectively (Tables 1-4), and estimates worldwide sales at twice the U.S. market sales. There are currently no competing products for the prevention or treatment of cancer therapy-induced alopecia or radiodermatitis. A single product has been FDA-approved for prevention of oral mucositis in bone marrow transplant patients only. As shown in Table 5, the adjunctive oncology therapy market is well established and attractive.

U.S. Cancer Patient Market Assumptions Table 1
Number of New Cancer Patients/Year 1.30 MM
Number of Cancer Patients with Recurrent Tumors/Year 0.65 MM
Total Number of Cancer Patients Treated/Year 1.90 MM
 
Percent of Patients Treated with Chemotherapy 50%
Number of Patients Treated with Chemotherapy 0.90 MM
 
Percent of Patients Treated with Radiotherapy 60%
Number of Patients Treated with Radiotherapy 1.14 MM


U.S. ProDermaCel Market Potential Table 2
Chemotherapy Patients 0.90 MM
Experience Alopecia x 50%
$/Patient x $900
Market $400 MM


U.S. DermX Market Potential Table 3
Radiotherapy Patients 1.14 MM
Experience Grade 2-4 Dermatitis x 50%
$/Patient x $600
Market $350 MM


U.S. OralX Market Potential Table 4
Radio/Chemotherapy Patients 1.14 MM
Experience Mucositis x 35%
$/Patient x $1,250
Market $500 MM


ADJUNCTIVE ONCOLOGY THERAPY
IS AN ATTRACTIVE MARKET		 Table 5
PRODUCT COMPANY INDICATION EST. U.S. SALES (2003)
Epogen Amgen Anemia $3,200 MM
Neupogen Amgen Neutropenia $2,100 MM
 
Zofran GlaxoSmithKline Antiemetic $1,400 MM
Kytril Roche Antiemetic $300 MM
 
OxyContin Purdue Cancer Pain $2,200 MM
Duragesic J&J Cancer Pain $1,700 MM
Oramorph SR Boehringer Cancer Pain $200 MM
 
MESNA BMS Cystitis $100 MM
Ethyol Medimmune Renal Toxicity $100 MM
     Total $11,300 MM

Source: Medical Advertising News/10k's